HGF and neoplasm: Our findings may thus indicate that targeting of HGF, a novel microenvironmental factor involved in CLL pathogenesis, could improve conventional therapies to cure this disease by inhibiting leukemic cell growth and by restoring specific immune responses against the tumor.